Legacy Investments

These are prior Capital Midwest Fund (CMF) investments that are not representative of CMF's strategy going forward. CMF no longer invests in pre-clinical or clinical-stage companies.

Adello Biologics [fka Therapeutic Proteins]

Adello Biologics is a biosimilar company focused on developing complex biologics for major regulated and strategic markets globally. Adello leverages single-use technology to operate nimbly while making biosimilar medications affordable.


EpiCare focuses on the development and sale of skin care and wound care products.

Gemphire Therapeutics (NASDAQ: GEMP)

Gemphire Therapeutics is developing gemcabene, a once-daily oral therapy, for patients who are unable to achieve normal levels of LDL ("bad") cholesterol or triglycerides with currently approved therapies, primarily statin therapy. Gemcabene’s dual mechanism of action is designed to both inhibit the production of fatty acids and cholesterol in the liver and enhances the clearance of very low-density lipoproteins in plasma.

Ocuphire Pharma [fka Ocularis Pharma]

To address the problem of night vision complaints due to light scatter, Ocuphire has patented the use of an entire class of molecules that have been demonstrated to inhibit pupil dilation in dim light.

PreEmptive Meds (PMI)

PMI’s products represent viable options for preempting disease or assisting in medical treatment and are supported by meaningful clinical data.

PrevaCept Infection Control [fka Great Lakes Pharmaceuticals]

PrevaCept Infection Control is a clinical stage company focused on development and commercialization of products designed to prevent infections associated with indwelling catheters.

Rapid Diagnostek

Rapid Diagnostek has developed a patented, point-of-care, biosensor-based platform appropriate for detecting proteins, bacteria, viruses, and other substances contained in liquid samples.

SeaStar Medical [fka CytoPherx]

SeaStar Medical has developed a patented hollow-fiber dialysis filter that sequesters and deactivates white blood cells to treat inflammation.

Sierra Oncology (NASDAQ: SRRA) [fka ProNAi Therapeutics (NASDAQ: DNAI)]

Sierra Oncology is a clinical-stage company advancing a pipeline of promising therapies that target the DNA Damage Response (DDR) network.